MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Section 3 clinical-stage biotechnology firm growing the investigational oral remedy, buntanetap, for neurodegenerative ailments comparable to Alzheimer’s illness (AD) and Parkinson’s illness (PD), right this moment introduced a partnership with NeuroRPM, a digital well being expertise firm, to implement a brand new FDA-cleared synthetic intelligence (AI) platform that collects motion information for symptom and illness administration in its ongoing Parkinson’s examine.
Annovis’ not too long ago launched open-label examine in PD sufferers (ANVS-25002) is at the moment enrolling members throughout the 25 websites in america to check buntanetap in the course of 36 months. As a part of the initiative to advance administration, monitoring, and information assortment, the Firm has entered right into a partnership with NeuroRPM to introduce the primary FDA-cleared AI-enabled medical system that enables to watch the first PD signs – bradykinesia, tremor, and dyskinesia. This data will function a digital biomarker, capturing real-time proof of how illness signs change in the course of the course of the examine.
“We are excited to collaborate with NeuroRPM and believe that data-driven insights generated from its platform will complement our existing data collection and strengthen the evidence-based monitoring of disease progression throughout the trial,” commented Cheng Fang, Ph.D., Senior Vice President, Analysis and Improvement at Annovis. “The data generated in this open-label study, together with novel biomarkers, will produce a wealth of information and provide additional insights into our understanding of the disease trajectory and will help inform the design of future clinical trials.”
NeuroRPM digital biomarker advantages:
AI-powered real-time detection of core Parkinson’s symptomsImproved entry to sufferers through cell and wearable applicationMedication monitoring and schedule remindersPassive information assortment that minimizes affected person burdenEnhanced understanding of therapy response in on a regular basis life
More Read
“Understanding the real-world impact of a therapy like buntanetap is a sophisticated task, particularly when treatment effects may unfold over multiple timescales across a highly variable patient population,” commented Atila Omer, CEO of NeuroRPM. “Continuous wearable monitoring enables objective measurement in real-world settings, helping researchers develop a more granular understanding of treatment response and a stronger evidence base for how a therapy is performing in daily life.”
For the open-label examine, along with the NeuroRPM’s digital biomarker assessing PD signs, Annovis can be implementing a extremely correct biomarker take a look at for misfolded phosphorylated alpha-synuclein – a defining hallmark of Parkinson’s pathology. Measured through a minimally invasive pores and skin process, the assay delivers goal pathological proof of the illness with larger than 90% diagnostic sensitivity and specificity. The mix of cutting-edge digital and organic biomarkers utilized in tandem opens a singular alternative to comprehensively report sufferers’ response to therapy – adjustments in signs and potential disease-modification – bringing larger precision and depth to the measurement of outcomes within the ongoing open-label PD trial.
About NeuroRPMHeadquartered in Washington D.C., NeuroRPM is a digital well being firm targeted on advancing the measurement and administration of Parkinson’s illness (PD) by way of steady, real-world monitoring and AI-enabled evaluation of advanced symptom and well being information. The corporate’s proprietary FDA 510(okay)-cleared expertise platform makes use of wearable sensors and AI-powered superior analytics to measure and quantify key motor signs of PD. By accumulating movement information repeatedly throughout regular every day actions, NeuroRPM offers goal perception into symptom patterns, fluctuations, and therapy response over time. NeuroRPM’s expertise is utilized in each scientific care and analysis to enrich conventional assessments with a extra steady and granular understanding of how PD presents in on a regular basis life.
More Read
About AnnovisHeadquartered in Malvern, PA, Annovis Bio, Inc. (NYSE: ANVS) is a Section 3 clinical-stage biotechnology firm growing therapies for neurodegenerative ailments comparable to Alzheimer’s illness (AD) and Parkinson’s illness (PD). The Firm’s lead drug candidate, buntanetap (previously posiphen), is an investigational once-daily oral remedy that inhibits the interpretation of a number of neurotoxic proteins, together with APP and amyloid beta, tau, alpha-synuclein, and TDP-43, by way of a selected RNA-targeting mechanism of motion. By addressing the underlying causes of neurodegeneration, Annovis goals to halt illness development and enhance cognitive and motor features in sufferers. For extra data, go to www.annovisbio.com and comply with us on LinkedIn, YouTube, and X.
Ahead-Trying StatementsThis press launch accommodates forward-looking statements below the Securities Act of 1933 and the Securities Change Act of 1934, as amended. Precise outcomes might differ attributable to varied dangers and uncertainties, together with these outlined within the Firm’s SEC filings below “Risk Factors” in its Annual Report on Type 10-Okay and Quarterly Stories on Type 10-Q. The Firm undertakes no obligation to replace forward-looking statements besides as required by legislation.
Contact Info:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA 19355www.annovisbio.com
